Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Outperform Rating at William Blair

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “outperform” rating reiterated by stock analysts at William Blair in a research report issued on Friday,RTT News reports.

Several other brokerages have also commented on ALNY. Scotiabank increased their price objective on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the company a “sector outperform” rating in a research report on Friday. Morgan Stanley boosted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $310.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. HC Wainwright boosted their price target on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. Finally, JPMorgan Chase & Co. raised their price objective on Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the company a “neutral” rating in a research note on Tuesday, March 11th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $308.74.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded up $30.75 during trading on Friday, hitting $284.30. The company had a trading volume of 1,644,711 shares, compared to its average volume of 796,166. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39. The stock has a market capitalization of $36.80 billion, a price-to-earnings ratio of -131.02 and a beta of 0.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The stock’s 50-day moving average is $256.25 and its two-hundred day moving average is $259.51.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Jeffrey V. Poulton sold 967 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the transaction, the chief financial officer now owns 32,786 shares of the company’s stock, valued at $8,366,003.62. The trade was a 2.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the sale, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock valued at $19,958,097 over the last ninety days. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ALNY. OneDigital Investment Advisors LLC purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter worth about $281,000. Natixis Advisors LLC purchased a new stake in Alnylam Pharmaceuticals in the third quarter worth approximately $2,751,000. Mutual of America Capital Management LLC grew its position in Alnylam Pharmaceuticals by 26.7% in the 3rd quarter. Mutual of America Capital Management LLC now owns 1,924 shares of the biopharmaceutical company’s stock worth $529,000 after purchasing an additional 405 shares during the period. Pathstone Holdings LLC raised its stake in Alnylam Pharmaceuticals by 11.2% during the 3rd quarter. Pathstone Holdings LLC now owns 6,249 shares of the biopharmaceutical company’s stock valued at $1,719,000 after buying an additional 629 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $902,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.